NDA 11123, held by Bristol Myers Squibb. Triflupromazine Hydrochloride.
As of Nov 14, 2026, NDA 11123 (Vesprin), held by Bristol Myers Squibb, was first approved by FDA on Sep 16, 1957, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 1957 | Original applicationNew molecular entity · Standard review | Approved | None posted |
| Vesprin10MG · tablet;oral | Triflupromazine Hydrochloride | Discontinued |
| Vesprin25MG · tablet;oral | Triflupromazine Hydrochloride | Discontinued |
| Vesprin50MG · tablet;oral | Triflupromazine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
